United States

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

July 67, 2026

Date of Report (Date of earliest event reported)

AIMEI HEALTH TECHNOLOGY CO., LTD

(Exact Name of Registrant as Specified in its Charter)

Cayman Islands		001-41880		N/A ~~00-0000000~~
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

10 East 53rd Street, Suite 3001

New York, NY

10022

(Address of Principal Executive Offices)

(Zip Code)

86-13758131392

Registrant’s telephone number, including area code

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

Securities registered pursuant to Section 12(b) of the Act:

Title of each Class	Trading Symbol(s)	Name of each exchange on which registered
Ordinary Shares, par value $0.0001 per share	AFJK	The Nasdaq Stock Market LLC
Rights, exchangeable into one-fifth of one Ordinary Share	AFJKR	The Nasdaq Stock Market LLC
Units, each consisting of one Ordinary Share and one Right	AFJKU	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 21.0302. ~~Creation~~Termination of a ~~Direct~~Material ~~Financial~~Definitive ~~Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant~~Agreement.

~~Extension~~As previously reported, on June 19, 2024 , Aimei Health Technology Co., Ltd (“Aimei Health” or the “Company”) entered into a definitive Business Combination Agreement (as amended on June 6, 2025, the “Business Combination Agreement”) for a business combination with (i) United Hydrogen Group Inc., an exempted company incorporated with limited liability in the Cayman Islands (“United Hydrogen”), (ii) United Hydrogen Global Inc., an exempted company incorporated with limited liability in the Cayman Islands, (iii) United Hydrogen Victor Limited, an exempted company incorporated with limited liability in the Cayman; (iv) United Hydrogen Worldwide Limited, an exempted company incorporated with limited liability in the Cayman Islands; and (v) Aimei Investment Ltd., a Cayman Islands exempted company, in the capacity as, from and after the closing of the ~~Termination~~transactions ~~Date~~contemplated by the Business Combination Agreement, the representative for Aimei Health and its shareholders.

AnOn ~~aggregate~~July of7, ~~$34~~2026,~~330.96~~ (the ~~“Extension~~Company ~~Payment”)~~delivered ~~has~~to ~~been~~United ~~deposited~~Hydrogen ~~into~~a ~~the~~notice ~~trust~~of ~~account~~termination of ~~Aimei Health Technology Co., Ltd (~~the ~~“Company”)~~Business ~~for~~Combination ~~its~~Agreement ~~public~~pursuant to ~~shareholders,~~Section ~~representing the lessor of~~ 9.1(ib) ~~$80~~thereof,~~000~~ ~~for~~effective ~~all~~the ~~outstanding public~~same ~~shares and (ii) $0~~day.~~033~~ ~~for~~As ~~each~~a ~~outstanding public share for each monthly extension~~result, ~~which enables~~ the ~~Company~~Business toCombination ~~further~~Agreement ~~extend the~~terminated ~~period~~in ofaccordance ~~time~~with ~~it has to consummate~~ its ~~initial business combination by one month (the “Extension”) from~~ ~~July 6~~terms, ~~2026~~and ~~to August 6, 2026 (~~the ~~“Termination~~proposed ~~Date”).~~business ~~The~~combination ~~Extension~~contemplated isby the ~~twentieth~~Business ~~extension~~Combination ~~permitted under~~Agreement ~~the~~will ~~Amended~~not ~~and~~be ~~Restated Articles of Association of the Company currently in effect~~consummated.

~~Promissory~~Item ~~Note~~7.01 Regulation FD Disclosure

InOn ~~connection with the Extension, the Company issued, on~~ July 67, 2026, ~~an unsecured promissory note in~~ the ~~total~~Company ~~principal~~issued ~~amount of $34,330.96 (the “Promissory Note”) to Aimei Health Ltd,~~ a ~~Cayman~~press ~~Islands~~release ~~exempted~~announcing ~~company (~~the ~~“Payee”), to~~termination ~~fund~~of the ~~Extension~~Business ~~Payment~~Combination Agreement. The ~~Promissory Note does not bear interest and the principal thereunder becomes due and payable upon the date on which the~~ Company ~~consummates a business combination with United Hydrogen (the “Business Combination”).~~ ~~The Payee~~ has ~~the~~filed ~~right,~~a ~~but~~copy ~~not the obligation, to convert the Promissory Note, in whole or in part, into private units~~ of the ~~Company, at~~press arelease ~~price~~as ofExhibit ~~$10~~99.001 ~~per unit~~hereto, ~~each consisting of one ordinary share~~ and ~~one~~it ~~right~~is toincorporated ~~receive one-fifth (1/5) of one ordinary share of the Company, immediately prior to the consummation of the Business Combination,~~ by ~~providing~~reference ~~the Company with written notices of their intention to convert the Promissory Note at least two business days prior to the closing of the Business Combination~~herein.

The foregoing ~~description~~(including ofExhibit ~~the~~99.1) ~~Promissory~~is ~~Note~~being isfurnished ~~not~~pursuant ~~complete~~to Item 7.01 and iswill ~~qualified~~not inbe ~~its~~deemed ~~entirety~~to bybe ~~reference~~filed tofor purposes of Section 18 of the ~~text~~Securities and Exchange Act of ~~such~~1934, ~~document~~as amended (the “Exchange Act”), or otherwise be subject to the liabilities ~~which~~of isthat ~~filed~~section, asnor ~~Exhibit~~will ~~10.1~~it ~~hereto~~be ~~and~~deemed ~~which~~to isbe incorporated ~~herein~~ by reference in any filing under the Securities Act or the Exchange Act.

Item 9.01 Exhibits.

(d) Exhibits

Exhibit No.		Description
10.1		Promissory Note, dated July 6, 2026, by and among Aimei Health Technology Co., Ltd, Aimei Health Ltd, and United Hydrogen Group Inc.
99.1		Press Release, dated July 8, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 68, 2026

	Aimei Health Technology Co., Ltd

	By:	/s/ Junheng Xie
	Name:	Junheng Xie
	Title:	Chief Executive Officer and Director
		(Principal Executive Officer)

Filing Compare · Aimei Health Technology Co., Ltd.